AZ enters Chinese medicine, siRNA leader targets the Chinese market, and the first biosimilar drug of aflibercept is applied for listing

AstraZeneca officially enters Chinese medicine

At the 2022 annual meeting of the Boao Forum for Asia, Chengdu and the participating company AstraZeneca (AZ) held an online signing ceremony for the AstraZeneca Chinese Medicine Innovation Industry Base

This move is regarded by the outside world as a sign of "AstraZeneca's official entry into traditional Chinese medicine", and it is another important layout of AstraZeneca in western China

siRNA leader forms joint venture Visirna to target China market

On April 25, Arrowhead Pharmaceuticals announced that it has formed a joint venture, Visirna Therapeutics, with Vivo Capital, which will be headquartered in Shanghai

Visirna has obtained an exclusive license to develop and commercialize four investigational RNAi therapeutics in Greater China for the treatment of cardiovascular and metabolic diseases, and will be solely responsible for the clinical development and commercialization of these products

Roche is challenged by biosimilars, sales in China fell 9% in the first quarter

On April 25, Roche released its 2022 Q1 financial report

Roche's pharmaceutical division recorded a revenue of CHF 11.

Novartis' revenue in China in the first quarter of 800 million US dollars, the growth rate is higher than that of Europe and the United States

On April 26, Novartis announced its financial report for the first quarter of 2022.
During the reporting period, the revenue was US$12.
531 billion and the net profit was US$2.
219 billion
.
Among Novartis TOP20 sales in the first quarter, sacubitril-valsartan (+42%) and libecili (+28%) grew the fastest, as did omalizumab, canakinumab and the "most expensive drug" Zolgensma achieved rapid growth
.

In terms of sub-regions, Novartis' revenue in the United States reached 3.
7 billion US dollars (+3%), and Europe's revenue was 3.
5 billion US dollars (+5%).
Although China's revenue was smaller than the previous two, it grew the fastest, with revenue of 800 million in the first quarter.
USD (+15%)
.

The new innovative medicines segment posted revenue of $10.
2 billion in the first quarter, mainly driven by sacubitril-valsartan, ofatumumab, secukinumab, omalizumab, Zolgensma and libecili
.
The generics division Sandoz had revenue of $2.
4 billion, which was mainly due to the tapering of the negative impact of COVID-19
.